Table 4.
Author / Year | Country | No. of cases | HPV (%) | Samples | Methods |
---|---|---|---|---|---|
Kaminagakura et al. [16] 2012 | Brazil | 114 | 19.2 | FFPE | GP5+/GP6+ |
Attner et al. [40] 2011 | Sweden | 87 | 78.0 | FFPE | GP5+/GP6+ |
Lopes et al. [25] 2011 | United Kingdom | 118 | < 2.0 | FTb/FFPE | GP5+/GP6+ |
Termine et al. [41] 2012 | Italy | 83 | 12.1 | FFPE | Nested PCRa PGMY09/11 |
Smith et al. [42] 2012 | USA | 170 | 9.4 | FFPE | GP5+/GP6+ PGMY09/11 |
Lee et al. [34] 2012 | Taiwan | 173 | 38.0 | FFPE | MY11/GP6+ |
Duray et al. [43] 2012 | Belgium | 147 | 44.2 | FFPE | GP5+/GP6+ |
Lingen et al. [26] 2013 | USA | 409 | 5.9 | FFPE | SPF10 |
González-Ramírez et al. [44] 2013 | Mexico | 80 | 5.0 | FTb | Nested PCRa |
Lopez et al. [13] 2014 | Brazil | 121 | 6.6 | FT/FFPE | PGMY09/11 |
Chakrobarty et al. [27] 2014 | India | 83 | 46.0 | FTb | MY09/MY11 |
aNested PCR, MY09/11 and GP5+/GP6+
bFT frozen tissue